HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights

He added, "With the recommended Phase 2 dose established in our early studies, we plan to expand into age- related indications in skin diseases and conditions associated with senescence. These studies will be designed as investigative studies, and we anticipate that it will be quicker to see human data read outs from this type of indication than would be possible in a cancer study. We are interested to see the aesthetic effects with the deep wrinkles and senile lentigo, perhaps as secondary endpoints." MIRA ...